Related Experiment Video
Updated: Feb 27, 2026
Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
Effects of atorvastatin on chronic subdural hematoma: A systematic review
Sheng Qiu1, Wang Zhuo, Chunming Sun
1Department of Neurosurgery, Huzhou Central Hospital, Huzhou, Zhejiang School of Nursing, Soochow University Department of Neurosurgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Insights
Atorvastatin may help reduce chronic subdural hematoma (CSDH) recurrence and absorption time. This systematic review suggests atorvastatin is a potentially safe and cost-effective CSDH treatment, warranting further investigation.
Area of Science:
- Neurosurgery
- Pharmacology
Background:
- Chronic subdural hematoma (CSDH) presents a high recurrence rate, posing challenges in neurosurgical management.
- The therapeutic role of atorvastatin for CSDH remains largely undetermined despite its potential safety and cost-effectiveness.
Purpose of the Study:
- To systematically review the existing literature on the efficacy of atorvastatin in managing CSDH.
- To evaluate the impact of atorvastatin on hematoma absorption, recurrence rates, and surgical intervention necessity in CSDH patients.
Main Methods:
- A comprehensive literature search was conducted across PubMed, EMBASE, Cochrane Library, and China Biology Medicine disc up to March 2017.
- Eligible studies were qualitatively analyzed to assess the efficacy of atorvastatin in CSDH management.
Main Results:
- The systematic review included three eligible studies.
- Findings suggest atorvastatin accelerates hematoma absorption and reduces the risk of CSDH recurrence and the need for surgery.
Conclusions:
- Preliminary evidence indicates that oral atorvastatin may offer benefits in CSDH management.
- Further high-quality research is required to determine optimal dosage, duration, and its effects based on hematoma size.
Background:
The high recurrent rate of chronic subdural hematoma (CSDH) has consistently confused the neurosurgeons, and the role of atorvastatin in the management of CSDH has remained unclear over past decade, and atorvastatin seems to be a safe and cost-effective treatment to CSDH. Therefore, it is necessary to conduct a systematic review to discuss the effect of atorvastatin in CSDH.
Method:
We searched the PubMed, EMBASE, Cochrane Library, and the China Biology Medicine disc, up to March 2017, for published studies on the effects of atorvastatin in the management of CSDH, and reviewers performed a brief qualitative descriptive analysis of atorvastatin's efficacy in the management of CSDH.
Results:
Three eligible studies were included in this systematic review. Results indicated that atorvastatin accelerated hematoma absorption, decreased recurrence risk, and surgical requirement.
Conclusion:
Limited evidence suggests that oral atorvastatin may be beneficial in the management of CSDH. Further high-quality studies focused on dosage, duration, hematoma size are needed to further elucidate the role of atorvastatin in the management of CSDH.
